IHS Chemical Week

Regions :: Western Europe :: Sweden

Swedish drugmaker Meda rejects Mylan's bid offer

9:51 AM MDT | April 28, 2014 | Natasha Alperowicz

In the latest wave of M&A frenzy in the pharma industry, Meda (Solna, Sweden) today rejected a revised bid offer by Mylan, the largest generic-drug company in the United States. “The board hereby confirms that it has been contacted by Mylan regarding a revised, nonbinding, indicative interest to combine the two businesses. The board has convened and has decided to reject the proposal. All contacts between Meda and Mylan have been terminated without further actions. The board’s decision is based on a strong belief in the continued potential of Meda...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa